Posted in | Nanomedicine | Nanobusiness

Global Market for Nanomaterials in Theranostics to Grow at 10.8% CAGR to $187 Billion in 2017 announces that a new market research report is available in its catalogue: Nanomaterials in Theranostics: Global Markets


This study provides a comprehensive analysis of the nanomaterial market for use in theranostics and personalized medicine. Theranostics is the fusion of therapy and diagnosis; it is the foundation of personalized medicine, which is a newly proposed model of highly customized healthcare. This study describes this model in detail and analyzes a large selection of nanomaterials that play various roles in the market, including proteins, monoclonal antibodies, nanoparticles, nanocrystals, liposomes and quantum dots.This market is increasing exponentially in size and revenues, and it is changing the standards of the healthcare model, thus imposing new marketing tactics, strategic alliances, innovative business models and research and development (R&D) outsourcing paradigms.This report addresses the drivers and limiters of this new model and offers an exhaustive analysis of the nanomaterials used in theranostics.


Theranostic and personalized medicine will be the ultimate transformation of modern healthcare to diagnose and treat diseases. Nanotechnology will be the toolbox used to execute this new approach to medicine. The report analyzes the market and includes historical sales of all the nanomaterials used in theranostics in 2011 and 2012. Sales are forecast through 2017.This study in an invaluable instrument for understanding the ways in which the pharmaceutical and medical device markets are rapidly changing by forming new paradigms and marketing strategies. The market is characterized by the creation of partnerships, collaborations and mergers and acquisitions (M&A) between pharmaceutical companies, the medical device industries, academics and small startups. Seventeen new emerging geographic markets, including Russia, India, China, Turkey, South Africa and Thailand, are also discussed.


Blockbuster and one–size-fits-all drugs are slowly exiting the market to make room for the era of personalized medicine. Theranostics, which is the fusion of therapeutics and diagnostics, is the foundation of personalized medicine in which specific therapies are tailored to patients to treat diseases based on their genetic makeups and/or to determine which therapies will have the fewest side effects. Nanotechnology will play a pivotal role in this revolution, and the global market for nanomaterials used in theranostics will be more than $187 billion in 2017, increasing at a compound annual growth rate (CAGR) of 10.8% Monoclonal antibodies will comprise the largest segment for the biologic nanomaterials, and liposome will be the largest segment for non-biologic nanomaterials. Other nanomaterials discussed in this report include fullerene C60, carbon nanotubes, quantum dots, gold nanoparticles and proteins.Profiles of key market players and small startups are also included. Major products that generate the largest revenues, as well as the most-valuable R&D products that will come on the market up to 2017 are provided.In-depth competitive market analysis is discussed, with examples of how new products will enter the market or how existing products will survive or perish. The report also includes a very detailed description of current and future technologies for the preparation of nanomaterials in theranostics.


The report is intended for professionals in the medical, medical devices, pharmaceutical, nanotechnology, materials, chemical, biological, biotechnological and diagnostics fields. It allows readers to understand the paradigms of personalized medicine's new business model. A discussion of the debate between the marketing of a drug with or without its companion diagnostic kit is included. Therefore, this report is valuable for both the pharmaceutical and the medical devices industries.Additional professionals who may benefit from reading this report include analysts, sales and marketing representatives, R&D personnel, business development personnel and corporate strategy developers. Investment firms will gain invaluable information concerning risks and opportunities encountered in the field.The report provides valuable insights and guidance for strategic marketing planning, driver and limiter understanding, and sales growth opportunities.


A bottom-up approached was used to calculate the global market size of nanomaterials for use in theranostics.Primary and secondary research was conducted using patent literature, paid and open-access academic literature, books, press (e.g., New York Times, Wall Street Journal) SEC filings, companies' annual reports and press releases.Interviews with experts in the field were conducted, including analysts, heads of investor relations and professors.Additional statistical data and general information were obtained from the National Science Foundation, the National Institutes of Health (NIH), the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), IMS Health and the Congressional Budget Office.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback